BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Bought by New York State Teachers Retirement System

New York State Teachers Retirement System grew its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 4.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 106,138 shares of the biotechnology company’s stock after buying an additional 4,057 shares during the period. New York State Teachers Retirement System owned 0.06% of BioMarin Pharmaceutical worth $6,976,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in BMRN. Creative Planning lifted its holdings in BioMarin Pharmaceutical by 20.9% in the third quarter. Creative Planning now owns 14,300 shares of the biotechnology company’s stock valued at $1,005,000 after acquiring an additional 2,475 shares during the last quarter. Vontobel Holding Ltd. raised its stake in shares of BioMarin Pharmaceutical by 73.0% in the third quarter. Vontobel Holding Ltd. now owns 6,050 shares of the biotechnology company’s stock valued at $425,000 after acquiring an additional 2,553 shares in the last quarter. nVerses Capital LLC acquired a new stake in shares of BioMarin Pharmaceutical in the third quarter valued at $28,000. Blue Trust Inc. increased its holdings in BioMarin Pharmaceutical by 504.9% in the third quarter. Blue Trust Inc. now owns 859 shares of the biotechnology company’s stock valued at $60,000 after buying an additional 717 shares during the last quarter. Finally, Sequoia Financial Advisors LLC purchased a new position in BioMarin Pharmaceutical in the third quarter valued at $279,000. 98.71% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts recently commented on BMRN shares. Royal Bank of Canada reissued a “sector perform” rating and issued a $80.00 target price on shares of BioMarin Pharmaceutical in a report on Wednesday, October 30th. Evercore ISI dropped their price objective on BioMarin Pharmaceutical from $115.00 to $105.00 and set an “outperform” rating on the stock in a report on Wednesday, October 30th. JPMorgan Chase & Co. lowered their price target on BioMarin Pharmaceutical from $110.00 to $109.00 and set an “overweight” rating on the stock in a report on Wednesday, October 30th. Canaccord Genuity Group lowered their price target on BioMarin Pharmaceutical from $93.00 to $84.00 and set a “hold” rating on the stock in a report on Wednesday, October 30th. Finally, Robert W. Baird reduced their price objective on shares of BioMarin Pharmaceutical from $72.00 to $65.00 and set a “neutral” rating for the company in a research report on Wednesday, October 30th. Seven investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $94.20.

BioMarin Pharmaceutical Trading Up 1.2 %

Shares of BMRN opened at $65.61 on Thursday. The company has a debt-to-equity ratio of 0.11, a current ratio of 4.27 and a quick ratio of 2.62. The firm has a 50 day simple moving average of $64.79 and a 200-day simple moving average of $71.10. BioMarin Pharmaceutical Inc. has a 1-year low of $60.63 and a 1-year high of $94.85. The stock has a market cap of $12.50 billion, a price-to-earnings ratio of 39.29, a price-to-earnings-growth ratio of 0.57 and a beta of 0.28.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings data on Wednesday, February 19th. The biotechnology company reported $0.72 earnings per share for the quarter, topping analysts’ consensus estimates of $0.54 by $0.18. BioMarin Pharmaceutical had a net margin of 11.71% and a return on equity of 8.53%. Equities analysts forecast that BioMarin Pharmaceutical Inc. will post 2.5 EPS for the current fiscal year.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.